Claude Maraoui Sells 18,147 Shares of Journey Medical Co. (NASDAQ:DERM) Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 18,147 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total value of $93,094.11. Following the completion of the sale, the chief executive officer now owns 2,092,874 shares of the company’s stock, valued at $10,736,443.62. This trade represents a 0.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Claude Maraoui also recently made the following trade(s):

• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The shares were sold at an average price of $5.19, for a total value of $122,006.52.

Journey Medical Price Performance

DERM stock opened at $5.06 on Friday. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. The business has a 50 day simple moving average of $4.56 and a 200-day simple moving average of $5.07. The firm has a market capitalization of $105.70 million, a PE ratio of -5.38 and a beta of 0.96. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89.

Institutional Investors Weigh In On Journey Medical

Large investors have recently made changes to their positions in the stock. Cetera Investment Advisers lifted its holdings in Journey Medical by 21.8% in the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after acquiring an additional 2,478 shares during the last quarter. Nwam LLC acquired a new position in Journey Medical in the third quarter valued at approximately $59,000. Kovitz Investment Group Partners LLC acquired a new position in Journey Medical in the third quarter valued at approximately $66,000. Dimensional Fund Advisors LP acquired a new position in Journey Medical in the fourth quarter valued at approximately $80,000. Finally, Citadel Advisors LLC acquired a new position in Journey Medical in the fourth quarter valued at approximately $174,000. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.